DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT

BIOMEDE is a multicentric randomized phase II trial to evaluate in DIPG the OS of patients treated with dasatinib, erlotinib or everolimus. The OS is the result of the first line treatment but it could also be affected by re-irradiation and the second line treatment received after progression, espec...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlo, Daniela Di, Pommier, Bertille, Teuff, Gwenael Le, Abbou, Samuel, Berlanga, Pablo, Geoerger, Birgit, Puget, Stephanie, Beccaria, Kevin, Blauwblomme, Thomas, Debily, Marie-Anne, Castel, David, Lechapt, Emmanuelle, Varlet, Pascale, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Vassal, Gilles, Deley, Marie-Cécile Le, Grill, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715765/
http://dx.doi.org/10.1093/neuonc/noaa222.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715765/
http://dx.doi.org/10.1093/neuonc/noaa222.106

Ejemplares similares